September 3, 2013, Northridge, CA. TriFoil Imaging today announced the signing of a definitive agreement to acquire privately-held Bioscan, Inc., a leading supplier of multimodal preclinical molecular imaging technologies. TriFoil and Bioscan will combine their robust in-vivo molecular capabilities and technical expertise to provide universities, pharmaceutical companies and contract research organizations with the highest quality imaging technologies. Outcome Capital, LLC served as exclusive financial advisor to Bioscan.
According to Kevin Parnham, President and CEO of TriFoil Imaging, “This is a tremendous opportunity for us to move forward as one entity dedicated to delivering the best possible imaging solutions for our customers. Bioscan enhances our offering with robust services capabilities along with additional imaging technologies, including 3D optical tomography.”
Joining TriFoil’s management team are Bioscan President and CEO, Staf Van Cauter, who will serve as VP, Sales, Marketing and Business Development, along with other critical employees. “We are very pleased to be joining the TriFoil team and look forward to continuing to serve our customer base with an expanded range of products,” stated Mr. Van Cauter. The combine brands will bolster our global footprint with the largest installed base of nuclear imaging equipment and will position Trifoil as a leading player in the preclinical imaging space”, added van Cauter.
The addition of Bioscan expands TriFoil Imaging’s product offering, which currently includes the Triumph II, a next generation pre-clinical tri-modality (PET/SPECT/CT imaging system, the eXplore CT120 In vivo MicroCT scanner, and now, BioFLECT, the first 360-degree optical imager, which uses a rotating ring of 48 detectors to generate a full 3-D scan of fluorescent markers.
“With world class technology, increased market intelligence and an expanded product line, this transaction will reinforce TriFoil Imaging’s leadership position in the market”, commented Robert C. Ammerman, Managing Partner, Capital Resource Partners, owner of TriFoil Imaging. He added, “The company is well-positioned to champion the imaging needs of researchers working on important projects throughout the world.”
About TriFoil Imaging Inc.
Leading research laboratories around the world depend on TriFoil Imaging (formerly Gamma Medica Ideas Pre-Clinical) technology to meet all their advanced in-vivo molecular imaging needs. Triumph TM is the world’s first tri-modality system (including PET, SPECT, and CT) to offer the highest quality and the best value by combining three modalities all in one reliable and easy-to-use system. Founded in 2001 and now owned by Capital Resource Partners, TriFoil is headquartered in Northridge, California. Please visit www.trifoilimaging.com to learn more.
Bioscan is a leading supplier of preclinical, molecular imaging solutions that enable groundbreaking life sciences research. Bioscan’s innovative nuclear (PET & SPECT), 3D optical, X-Ray CT and MRI imaging tools are used by more than 100 leading academic and government research institutions and life sciences companies worldwide to improve their disease, drug discovery and development research. Bioscan is based in Washington, DC, USA. Please visit www.bioscan.com to learn more.
Boston – November 8, 2023 Outcome Capital, a specialized life science advisory and investment banking firm, today announced that Electronic Registry Systems, Inc. (ERS), a leading provider of cancer registry solutions and compliance and informatics services, has been acquired by Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare technology and data analytics company with […]Read More
Outcome Capital Life Science Market Pulse October 2023 Click to view our LifeSciences Pulse NewsletterDownload